Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Stoke Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 8, 11:07PM CDT

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label...

STOK : 32.64 (-0.76%)
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates Business Wire - Thu May 7, 3:01PM CDT

– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics' Mounting Losses May Actually Validate Its Platform Better Than a Profit Would Barchart - Wed May 6, 4:32PM CDT

Barchart Research What to Expect from STOK Earnings STOK Generated May 6, 2026 Current Price $33.28 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 6.37% Stoke Therapeutics' Mounting Losses...

STOK : 32.64 (-0.76%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates Business Wire - Thu Apr 30, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Thu Apr 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 8, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire - Tue Apr 7, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Faces Mounting Losses as Earnings Loom Barchart - Tue Mar 24, 4:06PM CDT

STOK : 32.64 (-0.76%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Tue Mar 17, 4:12PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire - Wed Mar 4, 4:06PM CST

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)

Barchart Exclusives

Berkshire Hathaway Just Upped Its Stake in Sumitomo Stock. Greg Abel Says It’s Holding for the Long Term. Barchart - Mon May 11, 6:30PM CDT
Berkshire Hathaway has raised its stake in Sumitomo to 10.05% as of May 7, crossing the 10% threshold in all five major Japanese trading houses and signaling a long-term “permanent” holding under CEO Greg Abel. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.